Director/PDMR Shareholding

RNS Number : 7836E

Redx Pharma plc

06 November 2015

 

REDX PHARMA PLC

("Redx" or "the Company")

Director/PDMR shareholding

The Company was informed on 5 November 2015 that on the same day certain directors acquired in aggregate 18,125 ordinary shares of 1p each ("Shares") in the Company, as follows:

Director	Previous holding	Shares purchased	Price per Share (p)	Resultant holding
				Number	Percentage
Frank Armstrong Chairman	11,765	6,250	80.0	18,015	0.03
Norman Molyneux Non-Executive Director	248,615	6,250	80.0	254,865	0.39
Peter Jackson Non-Executive Director	3,268,374	5,625	80.0	3,273,999	5.04

For further information, please contact:

Redx Pharma Plc		T: 0151 706 4747
Neil Murray, Chief Executive Company website: redxpharma.com
Shore Capital (Nomad and Broker)		T: 020 7408 4090
Bidhi Bhoma / Patrick Castle / Edward Mansfield
KTZ Communications		T: 020 3178 6378
Katie Tzouliadis

About Redx Pharma Plc

Redx is focused on the development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 13 proprietary, (patent-protected) drug programs. Five programs have now achieved pre-clinical proof of concept, with relevance for respective therapies to treat MRSA, bone tumours, skin, brain, breast, pancreatic and blood cancers.  

 

END

 

 

RDSUVUWRVSAARAA